Capsulution Expands its Developmental Facilities

New projects on anti-cancer substances
(PresseBox) (Berlin, ) In July, Capsulution started to expand its laboratory facilities and thus adapt to the growing customer demand.

The aim is to develop Nanotechnology-based delivery systems for cytotoxic substances, like they are employed in modern cancer therapy. Such active compounds require both special laboratory and occupational health and safety conditions. Therefore, a high development quality and safety standard will be secured by a new, separate working area at Capsulution.

The new laboratory equipment will also be employed for example within the framework of cooperation with AcriTec AG and Schering AG, as was announced in March. According to this cooperation, the companies will concentrate on the development of special hydro-gels that on the one hand have the quality for best possible usage and transport and on the other hand are capable for the controlled release of embedded nanoparticles. These nanoparticles contain active substances and the release of them can take place via a controlled time frame. The combination of functional hytro-gels and embedded nanoparticles enables a targeted release of active substances, which reduces the dosage frequency of the application and increases the therapy safety.

“The extension of the laboratory technology is a vital key to success for our customers and staff alike and at the same time motivates us to further our product development more effectively under the most modern conditions,” states Lutz Kröhne, project director at Capsulution. The handling of highly effective new active components (NCEs) will soon be possible too with the help of our new laboratory technology.


Capsulution Pharma AG
Volmerstr. 7b
D-12489 Berlin
Dipl.-Kfm. Alexander Herrmann
Capsulution NanoScience AG
Chief Financial Officer (CFO)
Social Media